S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

$7.98
+0.28 (+3.64%)
(As of 03/18/2024 ET)
Today's Range
$7.27
$8.12
50-Day Range
$1.90
$10.13
52-Week Range
$1.87
$41.00
Volume
1.11 million shs
Average Volume
9.77 million shs
Market Capitalization
$472.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.71

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
172.6% Upside
$21.75 Price Target
Short Interest
Bearish
19.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Ventyx Biosciences in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$162,155 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

604th out of 946 stocks

Pharmaceutical Preparations Industry

274th out of 430 stocks

VTYX stock logo

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

VTYX Stock News Headlines

They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
VTYX Apr 2024 17.500 call
VTYX Apr 2024 10.000 put
AI Cracks Open Largest Untapped Energy Reserve on Earth
This orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… 
Ventyx Biosciences (NASDAQ:VTYX) Stock Price Up 5%
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTYX
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$62.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+184.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
9 Analysts

Profitability

Net Income
$-192,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.13 per share

Miscellaneous

Free Float
44,800,000
Market Cap
$472.82 million
Optionable
Optionable
Beta
0.36
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Sheila K. Gujrathi M.D. (Age 54)
    Executive Chairperson
    Comp: $125k
  • Dr. Raju S. Mohan Ph.D. (Age 67)
    Founder, CEO, President & Director
    Comp: $989.99k
  • Dr. John M. Nuss Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $656.99k
  • Dr. Martin Douglas Auster M.D. (Age 49)
    Chief Financial Officer
  • Mr. Christopher W. Krueger J.D. (Age 56)
    MBA, Chief Business Officer
    Comp: $568.14k

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings
or view top-rated stocks.

What is Ventyx Biosciences' stock price target for 2024?

9 Wall Street analysts have issued 12 month price targets for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they expect the company's stock price to reach $21.75 in the next twelve months. This suggests a possible upside of 172.6% from the stock's current price.
View analysts price targets for VTYX
or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 on January 1st, 2024. Since then, VTYX stock has increased by 223.1% and is now trading at $7.98.
View the best growth stocks for 2024 here
.

Are investors shorting Ventyx Biosciences?

Ventyx Biosciences saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 9,190,000 shares, an increase of 64.4% from the February 14th total of 5,590,000 shares. Based on an average daily volume of 4,450,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 19.5% of the shares of the company are short sold.
View Ventyx Biosciences' Short Interest
.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast
.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same period in the previous year, the company posted ($0.62) EPS.

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share.

Who are Ventyx Biosciences' major shareholders?

Ventyx Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.34%), Vanguard Group Inc. (6.32%), Capital International Investors (3.99%), Goldman Sachs Group Inc. (2.31%), Goldman Sachs Group Inc. (2.30%) and Opaleye Management Inc. (1.93%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White.
View institutional ownership trends
.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners